Peptides: Clinical Trials

16 trials of Peptides, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 16 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 116Completed 12, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Unknown 1

Follow Peptides: new trials by email Literature Review of Peptides trials Research Report on Peptides

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Personalized Vaccine for TNBC Immunotherapy
Peptide (neoantigen) pulsed autologous Dendritic cell - Breast Cancer Female
Phase 1Not yet recruitingUniversidad Nacional de Colombia82025-08-012025-06-25
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab - Biliary Tract Cancers
Phase 1RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins252025-05-272026-05-08
Evaluation of the Effect of Self-Assembling Peptide P11-4
Peptide - Dental Caries
Phase 1CompletedEgymedicalpedia302021-07-012023-01-06
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
Peptide, Anti-PD-1, rhGM-CSF - Melanoma (Skin)
Phase 1UnknownXiangya Hospital of Central South University302020-04-212020-04-28
Phase 1A Study of the Safety of KSP/QRH Dimer
KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg, KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg - Healthy Adults
Phase 1CompletedUniversity of Michigan262018-08-222018-11-06
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
Poly-ICLC, Tumor Treating Fields, Peptides - Glioblastoma
Phase 1Active not recruitingAdilia Hormigo132018-03-012026-09-21
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
Fimaporfin (Photosensitizer), Hiltonol (Poly-ICLC), HPV E7 (Human Papilloma Virus E7) peptides - Healthy Volunteer
Phase 1CompletedPCI Biotech AS962016-09-012019-08-28
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
Peptides, Poly-ICLC, Lenalidomide - Solid Tumors
Phase 1CompletedNina Bhardwaj132016-04-012021-01-11
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Poly-ICLC, Peptides - Melanoma
Phase 1CompletedPatrick Ott, MD, PhD152014-04-012025-12-29
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V) - Melanoma (Skin)
Phase 1CompletedH. Lee Moffitt Cancer Center and Research Institute732010-08-132023-07-19
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
CP 870,893, Peptides, Oncovir poly IC:LC - Melanoma
Phase 1CompletedH. Lee Moffitt Cancer Center and Research Institute222009-10-012015-09-24
Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection
peptide vaccine (AFO-18) - HIV INFECTIONS
Phase 1CompletedGitte Kronborg112009-09-012014-03-27
Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured
Autologous dendritic cell-adenovirus CCL21 vaccine - Melanoma (Skin)
Phase 1CompletedH. Lee Moffitt Cancer Center and Research Institute132008-11-012012-09-24
Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants
Peptides (N,R&C) formulated in Montanide ISA 720, Peptides (N,R&C) formulated in Montanide ISA 51, Placebo - Malaria, Vivax
Phase 1CompletedMalaria Vaccine and Drug Development Center402005-07-012010-03-08
Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine
KLH; Peptides; Dendritic Cells, KLH, peptides plus Montanide - Melanoma
Phase 1CompletedDr. Nina Bhardwaj502005-07-012015-02-13
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
gp100:209-217(210M) Peptide Vaccine, HPV 16 E7:12-20 Peptide Vaccine, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IA Skin Melanoma
Phase 1CompletedNational Cancer Institute (NCI)302002-10-012015-01-26

Conditions studied

Melanoma (7)  ·  Neoplasms (2)  ·  Biliary Tract Neoplasms (1)  ·  Brain Neoplasms (1)  ·  Carcinoma (1)  ·  Dental Caries (1)  ·  Diabetes Mellitus, Insulin-Dependent, 12 (1)  ·  Glioblastoma (1)  ·  HIV Infections (1)  ·  Malaria (1)  ·  Malaria, Vivax (1)  ·  Neoplasm Metastasis (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

H. Lee Moffitt Cancer Center and Research Institute (3)  ·  Adilia Hormigo (1)  ·  Dr. Nina Bhardwaj (1)  ·  Egymedicalpedia (1)  ·  Gitte Kronborg (1)  ·  Malaria Vaccine and Drug Development Center (1)  ·  National Cancer Institute (NCI) (1)  ·  Nina Bhardwaj (1)  ·  PCI Biotech AS (1)  ·  Patrick Ott, MD, PhD (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  Universidad Nacional de Colombia (1)  ·  University of Michigan (1)  ·  Xiangya Hospital of Central South University (1)

Countries

United States (10)  ·  Colombia (2)  ·  China (1)  ·  Denmark (1)  ·  Egypt (1)  ·  United Kingdom (1)

Top investigators

Nina Bhardwaj, MD, PhD (2)  ·  Adilia Hormigo, MD, PhD (1)  ·  Anders Fomsgaard, MD (1)  ·  Asmaa Mosleh, Lecturer (1)  ·  Deepa Chandhrasekhar, BS (1)  ·  Gitte Kronborg, MD (1)  ·  Jan Gerstoft, MD (1)  ·  Jeffrey S. Weber, MD, PhD (1)  ·  Jeffrey Weber, M.D., Ph.D. (1)  ·  Jim Bush, MBChB, PhD, MRCS, MFPM (1)  ·  Marina Baretti, MD (1)  ·  Myriam Arevalo-Herrera, PhD (1)  ·  Nikhil Khushalani, M.D. (1)  ·  Patrick Ott, MD, PhD (1)  ·  Sylvia Adams, MD (1)

Results publications

PMID 23314272, PMID 28678778, PMID 28678784, PMID 33479501, PMID 33488576, PMID 34311780, PMID 36450385

NIH funding

2008 (1), R21CA099265 (1)